Yahoo Finance

Operations: The company's primary revenue stream is from Intravenous Infusion Solution and Others, generating HK$5.59 billion, while Medical Materials contribute HK$405.07 million. Over recent periods, the net profit margin has shown a notable upward trend, reaching 21.11% by mid-2024 before declining to 18.38% by year-end 2024.

PE: 8.2x

SSY Group, a smaller player in Asia's pharmaceutical sector, is gaining traction with recent product approvals from China's National Medical Products Administration. These include drugs for diabetes and hypertension, which could enhance their market position. Despite a decrease in sales to HK$5.77 billion for 2024, insider confidence is evident as an executive purchased 1.4 million shares worth approximately HK$4.72 million between March and April 2025. Earnings are projected to grow by over 12% annually, though reliance on external borrowing poses some risk.

• Take a closer look at SSY Group's potential here in our valuation report.

• Gain insights into SSY Group's past trends and performance with our Past report.

Shougang Fushan Resources Group

Simply Wall St Value Rating: ★★★★★☆

Overview: Shougang Fushan Resources Group is primarily engaged in coking coal mining operations with a market capitalization of HK$11.76 billion.

Operations: The company primarily generates revenue from coking coal mining, with recent revenue reported at HK$5.06 billion. The gross profit margin has shown variability, peaking at 68.34% in mid-2022 and declining to 51.18% by the end of 2024. Operating expenses have been a consistent part of the cost structure, with sales and marketing expenses comprising a notable portion within this category.

PE: 8.4x

Shougang Fushan Resources Group, a smaller player in the Asian market, has caught attention with insider confidence as Deputy MD & Executive Director Zhaoqiang Chen acquired 640,000 shares recently. Despite a dip in sales to HK$5 billion and net income to HK$1.49 billion for 2024 compared to the previous year, the company proposed a dividend increase of HK$0.21 per share. The appointment of Mr. Xu Qian as non-executive director adds financial expertise amid an auditor rotation for enhanced governance practices.

• Delve into the full analysis valuation report here for a deeper understanding of Shougang Fushan Resources Group.

• Gain insights into Shougang Fushan Resources Group's historical performance by reviewing our past performance report.

Turning Ideas Into Actions

• Discover the full array of 65 Undervalued Asian Small Caps With Insider Buying right here.

• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include PSE:SECB SEHK:2005 and SEHK:639.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com